Obviously, these guys are running for cover: no plans for Australia, no plant in USA, lots of debt to cover....no creditibility...I am surprised the price has held...
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%